News und Analysen
![Premier Inc. Named One of the 2020 World’s Most Ethical Companies® by Ethisphere® Institute for the 13th Year in a Row](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Premier Inc. Named One of the 2020 World’s Most Ethical Companies® by Ethisphere® Institute for the 13th Year in a Row
Premier Inc., a leading healthcare improvement company, has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2020
![Xencor Reports Fourth Quarter and Full Year 2019 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![Chemed Corporation Declares Quarterly Dividend of 32 Cents](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Chemed Corporation Declares Quarterly Dividend of 32 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 32-cents per share on the Company’s capital stock, payable on March 23, 2020, to
![Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio
Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest
![QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Nigeria, the country with the largest population in Africa and one of the world’s 30 high-disease burden countries for
![ICON Acquires MedPass International](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
ICON Acquires MedPass International
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has
![QIAGENs QuantiFERON®-TB Gold Plus als Test auf latente TB wird in Nigeria eingeführt](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGENs QuantiFERON®-TB Gold Plus als Test auf latente TB wird in Nigeria eingeführt
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass Nigeria, das Land mit der größten Bevölkerung und eines der 30 Länder mit der höchsten Tuberkuloselast, im Rahmen
![New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
![Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare
![Chemed Reports Fourth-Quarter 2019 Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Chemed Reports Fourth-Quarter 2019 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
![Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent
Medicare Accountable Care Organizations (ACOs) participating in the Premier Inc. (NASDAQ: PINC) Population Health Management Collaborative (PHMC) have outperformed their peers by 21 percent in
![Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will
![Canopy Growth: Das war der Befreiungsschlag!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Canopy Growth: Das war der Befreiungsschlag!
Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im
![Canopy Growth: Was Aurora kann...](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
![Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020. For the quarter, revenue was $691.1
![Xencor to Present at Upcoming Investor Conferences](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
![Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an
![QIAGEN meldet Ergebnisse für das vierte Quartal und das Geschäftsjahr 2019](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
QIAGEN meldet Ergebnisse für das vierte Quartal und das Geschäftsjahr 2019
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse der operativen Tätigkeit für das vierte Quartal und das Gesamtjahr 2019 bekannt.
„QIAGENs Ergebnisse des vierten
![QIAGEN Reports Results for Fourth Quarter and Full-Year 2019](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN Reports Results for Fourth Quarter and Full-Year 2019
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.
“QIAGEN’s performance for the fourth quarter and full-year 2019
![Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has entered into a definitive agreement to acquire substantially all the assets and certain
![Premier Inc. Reports Fiscal 2020 Second-Quarter Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Premier Inc. Reports Fiscal 2020 Second-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 second quarter ended Dec. 31, 2019.
All results presented in this press release reflect continuing operations
![QIAGEN führt FFPE- und Flüssigbiopsie-PIK3CA-Diagnostika in Europa ein, um die Präzisionsmedizin bei fortgeschrittenem Brustkrebs zu verbessern](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
QIAGEN führt FFPE- und Flüssigbiopsie-PIK3CA-Diagnostika in Europa ein, um die Präzisionsmedizin bei fortgeschrittenem Brustkrebs zu verbessern
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die CE-Kennzeichnung und die Einführung des therascreen® PIK3CA RGQ PCR-Kits in Europa zur Identifizierung von
![QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients
![Acceleron Pharma: Bluthochdruck!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Acceleron Pharma: Bluthochdruck!
Die Aktie von Acceleron Pharma (WKN: A1W5LE) gehört heute zu den ganz großen Gewinnern am US-Aktienmarkt und kann um sage und schreibe mehr als +50% zulegen.
Dabei handelt es sich bei Acceleron